 AstraZeneca PLC LSE:AZN shares were among the top risers on the FTSE 100 after it received a triple dose of good news, including backing from the European Union drug regulator for its Covid-19 treatment. Evusheld, a long-acting antibody combination, has been recommended for approval in the EU for those older than 12 years with Covid who do not require supplemental oxygen and who are at increased risk of progressing to severe form of the disease. 